Life Sciences

  • December 16, 2025

    Va. Judge Advances Most Claims In Stelara Antitrust Case

    A Virginia federal judge has allowed health insurer CareFirst's anticompetition and patent fraud claims against Johnson & Johnson to move forward in a case alleging anticompetitive behavior in relation to the immunosuppressive drug Stelara, while letting the pharmaceutical giant escape some claims of misrepresentation.

  • December 16, 2025

    Trump Executive Order Calls Fentanyl A 'WMD'

    President Donald Trump has declared fentanyl a "weapon of mass destruction," according to an executive order that explicitly calls on the military to respond to "chemical incidents in the homeland."

  • December 16, 2025

    The Most Important Healthcare And Life Science Deals Of 2025

    Attorneys taking stock of 2025 spoke to Law360 about the most important deals of the year, including Pfizer’s high-profile acquisition of Metsera and transactions in outpatient services and gene therapy.

  • December 16, 2025

    Trends That Shaped Healthcare Dealmaking In 2025

    With 2025 coming to a close, Law360 Healthcare Authority asked attorneys focused on healthcare deals for their take on the trends that influenced dealmaking over the last 12 months.

  • December 16, 2025

    Merck Sued Over Time Rounding, OT Averaging At NC Plant

    A Merck manufacturing facility in North Carolina rounded workers' time to short them on pay, averaged out overtime across two weeks and fired an operator technician because of his sleep apnea, the worker told a federal court in a proposed class and collective action against the pharmaceutical giant.

  • December 16, 2025

    Jury Says Magnolia Medical Is Owed $1.6M After Patent Trial

    A Delaware federal jury on Tuesday morning found that Magnolia Medical Technologies Inc. is entitled to nearly $1.6 million after Kurin Inc. infringed its patents tied to devices meant for drawing blood.

  • December 16, 2025

    5 Big Litigation Developments Out Of Georgia In 2025

    It was a busy year for courts in Georgia, with a federal judge ordering the state's corrections system to continue providing hormone therapy to transgender people in prison, and prosecutors deciding to drop the historic racketeering case against President Donald Trump and his allies. Here, Law360 recaps the biggest legal developments to come out of Peach State courts in 2025.

  • December 16, 2025

    Another Dechert IP Atty Leaves, This Time For Morgan Lewis

    Morgan Lewis LLP has added another departing member of the Dechert LLP intellectual property team, who joins the firm in Boston after Dechert's global intellectual property practice co-chair, two partners, and a total of 30 professionals moved to Cooley LLP last week.

  • December 16, 2025

    Medical Device Maker Zynex Hits Ch. 11 With Sale Plans

    Zynex Inc., a pain management medical device maker, filed for bankruptcy protection in Texas with at least $66.7 million in debt and plans to sell the business backed by a stalking horse bid from its creditors.

  • December 15, 2025

    Smartwatch Giants Sued Over Fall Detection Patents

    A company that makes medical alert watches for the elderly has sued Apple, Samsung, Google and Garmin in federal court and the U.S. International Trade Commission, alleging that the fall detection features in their smartwatches infringe two patents.

  • December 15, 2025

    States Fight Sandoz Bid To Argue Duplication In Generics Row

    Multiple attorneys general have told a Connecticut federal court that Sandoz Inc. and Fougera Pharmaceuticals Inc. can't claim the states' grievances over allegations of price fixing are duplicative of claims that were already settled, since there are some claims and forms of relief that only state plaintiffs can seek.

  • December 15, 2025

    DOJ Raises Accreditation Concerns In Vet School Case

    The U.S. Department of Justice waded into a Tennessee veterinary school's antitrust case challenging the American Veterinary Medical Association's accreditation requirements, raising concerns about the risk posed by professional groups that play gatekeeping functions.

  • December 15, 2025

    Ohio Gov. To Designate Synthetic Kratom Extract Illegal Drug

    Ohio Gov. Mike DeWine is looking to immediately ban synthetic kratom compounds while simultaneously seeking to either ban or heavily regulate the active ingredient in "natural kratom," citing serious public health concerns.

  • December 15, 2025

    Formula Suits An 'Undue Burden' On Cook County, Panel Says

    An Illinois appellate court Friday agreed with Abbott Laboratories that 23 lawsuits alleging the company failed to warn of important risks associated with infant formulas and caused premature babies to develop necrotizing enterocolitis should not have been filed in Cook County, where the infants at the center of those cases were not born and have never lived.

  • December 15, 2025

    USPTO Replaces Denver Office With Center In Montana

    Montana has been picked by the U.S. Patent and Trademark Office to be the first state to oversee community outreach in the area formerly serviced by the now-shuttered Rocky Mountain Regional Outreach Office in Denver.

  • December 15, 2025

    Cencora Pays $5B For Majority Stake Of OneOncology

    Pharmaceutical company Cencora Inc. unveiled plans Monday to acquire a majority stake in cancer care company OneOncology for $5 billion, buying interest from private equity shop TPG in a deal built by three law firms.

  • December 15, 2025

    Connecticut 'Likely' To Settle Generic Drug Price Cap Dispute

    A pharmaceutical industry trade group and the state of Connecticut have signaled their intent to settle a feud over the interpretation of the state's generic drug price cap law, and a federal judge gave them until Monday to say more about their plan.

  • December 15, 2025

    Fed. Circ. Won't Revive Bard Patents In AngioDynamics Row

    The Federal Circuit on Monday refused to revive claims in C.R. Bard patents on implanted catheter receptacles that were challenged by AngioDynamics, backing a Delaware federal court's finding that the claims were anticipated.

  • December 15, 2025

    Blank Rome Hires Baker McKenzie Litigator In DC

    Blank Rome LLP has hired a Baker McKenzie litigator who focuses his practice on technology, life sciences, aerospace, government contracts and energy industry-related matters to join the team in Washington, D.C., as a partner, the firm announced Monday.

  • December 15, 2025

    The Top Patent Decisions Of 2025

    The Federal Circuit decided its first en banc utility patent case in years and expanded who can use the U.S. International Trade Commission, while both the appeals court and U.S. Patent and Trademark Office took on the eligibility of AI patents. Here's a look at the top patent decisions of 2025.

  • December 15, 2025

    PTAB Creates New Prehearing Conference For AIA Reviews

    The Patent Trial and Appeal Board has rolled out a change to its trial practice guide that will create a new prehearing conference 15 days prior to oral hearings under the America Invents Act in cases implemented by the U.S. Patent and Trademark Office director.

  • December 15, 2025

    High Court Won't Review Doctor 'Upcoding' Acquittal Decision

    The U.S. Supreme Court said Monday that it won't review a decision allowing a retrial of a Maryland doctor who was initially found guilty of a COVID-19 testing scheme but then secured an acquittal.

  • December 15, 2025

    Supreme Court Declines Cannabis Ban Review

    The U.S. Supreme Court on Monday declined to hear a case challenging the federal marijuana ban, leaving in place a high court precedent that has governed cannabis policy for 20 years.

  • December 15, 2025

    Supreme Court Turns Down Entresto Patent Fight

    The U.S. Supreme Court on Monday rejected a petition from MSN Pharmaceuticals Inc. claiming the Federal Circuit improperly applied what is known as after-arising technology when reviving a patent covering Novartis Pharmaceuticals Corp.'s blockbuster cardiovascular drug Entresto.

  • December 15, 2025

    McDermott-Led Sobi To Buy US Gout Specialist For $1.5B

    Swedish biopharma company Swedish Orphan Biovitrum AB said Monday that it has agreed to acquire Arthrosi Therapeutics Inc., a specialist in treatment for gout, for up to $1.5 billion in a deal guided by McDermott.

Expert Analysis

  • Opinion

    High Court, Not A Single Justice, Should Decide On Recusal

    Author Photo

    As public trust in the U.S. Supreme Court continues to decline, the court should adopt a collegial framework in which all justices decide questions of recusal together — a reform that respects both judicial independence and due process for litigants, say Michael Broyde at Emory University and Hayden Hall at the U.S. Bankruptcy Court for the District of Delaware.

  • Series

    Traveling Solo Makes Me A Better Lawyer

    Author Photo

    Traveling by myself has taught me to assess risk, understand tone and stay calm in high-pressure situations, which are not only useful life skills, but the foundation of how I support my clients, says Lacey Gutierrez at Group Five Legal.

  • Latest PTAB Moves Suggest A Subtle Recalibration

    Author Photo

    Recent decisions from the Patent Trial and Appeal Board, as U.S. Patent and Trademark Office Director John Squires transitions into his new role, offer new procedural and substantive tools for patent owners in procuring patent rights and enforcing them against would-be petitioners, say attorneys at Morgan Lewis.

  • Opinion

    DOJ's Tracing Rule For Pandemic Loan Fraud Is Untenable

    Author Photo

    In conducting investigations related to COVID-19 relief fraud, the government's assertion that loan proceeds are nonfungible and had to have been segregated from other funds is unsupported by underlying legislation, precedent or the language establishing similar federal relief programs, say Sharon McCarthy, Jay Nanavati and Lasya Ravulapati at Kostelanetz.

  • Del. Ruling Reaffirms High Bar To Plead Minority Control

    Author Photo

    The Delaware Court of Chancery's recent decision in Witmer v. Armistice maintains Delaware's strict approach to control and provides increased predictability for minority investors in their investment and corporate governance decisions, says Elena Davis at Ropes & Gray.

  • Series

    Law School's Missed Lessons: Client Service

    Author Photo

    Law school teaches you how to interpret the law, but it doesn't teach you some of the key ways to keeping clients satisfied, lessons that I've learned in the most unexpected of places: a book on how to be a butler, says Gregory Ramos at Armstrong Teasdale.

  • How Occasional Activists Have Reshaped Proxy Fights

    Author Photo

    The sophistication and breadth of first-time activist engagement continue to shape corporate governance and strategic outcomes, as evidenced across corporate annual meetings this summer, meaning advisers should anticipate continued innovation in tactics, increased regulatory complexity, and a persistent focus on board accountability, say attorneys at MoFo.

  • What To Expect After FDA Warnings To GLP-1 Compounders

    Author Photo

    The U.S. Food and Drug Administration's recent warning letters to companies advertising compounded versions of GLP-1 medications raise questions not just about the enforcement outlook for marketing such products, but also about the future of drug compounding as a whole, say attorneys at Spencer Fane.

  • Where 4th And 9th Circ. Diverge On Trade Secret Timing

    Author Photo

    Recent Fourth and Ninth Circuit decisions have revealed a deepening circuit split over when plaintiffs must specifically define their alleged trade secrets, turning the early stages of trade secret litigation into a key battleground and elevating the importance of forum selection, say attorneys at Skadden.

  • Series

    Adapting To Private Practice: 3 Tips On Finding The Right Job

    Author Photo

    After 23 years as a state and federal prosecutor, when I contemplated moving to a law firm, practicing solo or going in-house, I found there's a critical first step — deep self-reflection on what you truly want to do and where your strengths lie, says Rachael Jones at McKool Smith.

  • Series

    Painting Makes Me A Better Lawyer

    Author Photo

    Painting trains me to see both the fine detail and the whole composition at once, enabling me to identify friction points while keeping sight of a client's bigger vision, but the most significant lesson I've brought to my legal work has been the value of originality, says Jana Gouchev at Gouchev Law.

  • Courts Are Still Grappling With McDonnell, 9 Years Later

    Author Photo

    The Seventh and D.C. Circuits’ recent decisions in U.S. v. Weiss and U.S. v. Paitsel, respectively, demonstrate that courts are still struggling to apply the U.S. Supreme Court’s 2016 ruling in McDonnell v. U.S., which narrowed the scope of “official acts” in federal bribery cases, say attorneys at Quinn Emanuel.

  • AI Will Transform Patent Examination For The Better

    Author Photo

    The U.S. Patent and Trademark Office's increasing use of artificial intelligence tools will result in patents that are more thoroughly vetted, and patent applicants and practitioners will need to adapt their drafting strategies and address stronger and more sophisticated rejections, say attorneys at Troutman.

  • Hybrid Claims In Antitrust Disputes Spark Coverage Battles

    Author Photo

    Antitrust litigation increasingly includes claims for breach of warranty, product liability or state consumer protection violations, complicating insurers' reliance on exclusions as courts analyze whether these are antitrust claims in disguise, says Jameson Pasek at Caldwell Law.

  • Drug Ad Crackdown Demonstrates Admin's Aggressive Stance

    Author Photo

    Recent actions by the U.S. Food and Drug Administration and U.S. Department of Health and Human Services targeting pharmaceutical companies' allegedly deceptive advertising practices signal an active — potentially even punitive — intent to regulate direct-to-consumer advertising out of existence, say attorneys at King & Spalding.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.